Dihydrofolate Reductase anticorps

N° du produit ABIN1387277

L’anticorps anti-Dihydrofolate Reductase Polyclonal Lapin est utilisé pour la détection de Dihydrofolate Reductase dans des échantillons de Humain. Il a été validé pour IF, IHC (p) et IHC (fro).

Aperçu rapide pour Dihydrofolate Reductase anticorps (ABIN1387277)

Antigène: Dihydrofolate Reductase (DHFR)

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp Dihydrofolate Reductase est non-conjugé

Application: Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))

Détail du produit anti-Dihydrofolate Reductase anticorps

Fonction: DHFR Polyclonal Antibody

Réactivité croisée: Humain, Souris

Purification: Purified by Protein A.

Immunogène: KLH conjugated synthetic peptide derived from human DHFR

Isotype: IgG

Information d'application

Indications d'application: IHC-P(1:200-400), IHC-F(1:100-500), IF(1:50-200)

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 μg/μL

Buffer: 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles.

Date de péremption: 12 months

Détails sur Dihydrofolate Reductase

Antigène: Dihydrofolate Reductase (DHFR)

Autre désignation: DHFR

Sujet:

Synonyms: DHFR, DHFRP1, Dihydrofolate reductase, DYR, DYR_HUMAN, EC 1.5.1.3.

Background: DHFR catalyzes the NADPH-dependent reduction of dihydrofolate to tetrahydrofolate, and is a crucial enzyme for the synthesis of purines, pyrimidines and some amino acids. Inhibition of the activity of this enzyme leads to arrest of DNA synthesis and cell death. Gene expression of methotrexate (MTX)-resistant variants of DHFR in normal hematopoietic cells is a potential strategy to permit administration of larger doses of MTX by alleviating drug toxicity in normal cells and tissues that are drug sensitive.

Poids moléculaire: 21kDa

ID gène: 1719

HGNC: 0

UniProt: P00374

Pathways: Mitotic G1-G1/S Phases